Rankings
▼
Calendar
REGN Q4 2021 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5.0B
+104.4% YoY
Gross Profit
$3.9B
78.7% margin
Operating Income
$2.6B
53.3% margin
Net Income
$2.2B
45.0% margin
EPS (Diluted)
$19.69
QoQ Revenue Growth
+43.4%
Cash Flow
Operating Cash Flow
$2.4B
Free Cash Flow
$2.2B
Stock-Based Comp.
$188M
Balance Sheet
Total Assets
$25.4B
Total Liabilities
$6.7B
Stockholders' Equity
$18.8B
Cash & Equivalents
$2.9B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5.0B
$2.4B
+104.4%
Gross Profit
$3.9B
$2.0B
+93.9%
Operating Income
$2.6B
$1.2B
+126.2%
Net Income
$2.2B
$1.1B
+94.0%
Revenue Segments
Product
$4.0B
98%
Product and Service, Other
$86M
2%
← FY 2021
All Quarters
Q1 2022 →